Familial Alzheimer's Disease (FAD) is a rare, autosomal dominant form of Alzheimer's Disease caused by highly penetrant mutations in one of three genes: presenilin-1 (PSEN1, presenilin-2 (PSEN2, or amyloid precursor protein (APP. FAD accounts for fewer than 5% of all AD cases but has been indispensable in establishing the mechanistic basis of the disease, providing the strongest genetic evidence for the amyloid cascade hypothesis Bateman et al., 2011. Affected individuals typically develop symptoms decades earlier than sporadic AD patients, with some PSEN1 carriers experiencing onset as young as 23 years of age. The study of FAD families has driven the development of anti-amyloid therapeutics and motivated landmark prevention trials in presymptomatic mutation carriers [2].
FAD follows a strict autosomal dominant inheritance pattern: a single copy of the pathogenic allele from either parent is sufficient to cause the disease. Each child of an affected parent has a 50% probability of inheriting the mutation. Unlike sporadic late-onset AD, where APOE epsilon-4 is the strongest genetic risk factor with incomplete penetrance, FAD mutations in PSEN1 and APP show virtually complete penetrance, meaning that nearly all carriers will develop the disease if they survive to the expected age of onset Ryman et al., 2014 [3].
| Feature | PSEN1 | PSEN2 | APP |
|---|---|---|---|
| Chromosome | 14q24.3 | 1q42.13 | 21q21.3 |
| Number of known pathogenic mutations | >300 | ~18 pathogenic (7 highly pathogenic) | >50 |
| Proportion of FAD cases | ~50-70% | <5% | 10-15% |
| Penetrance | Virtually complete (>99%) | Incomplete (~95%) | Virtually complete |
| Age of onset range | 24-60 years (mean ~43) | 40-85 years (mean ~57) | 40-65 years (mean ~52) |
| Primary mechanism | Altered gamma-secretase cleavage; increased Abeta42/40 ratio | Altered gamma-secretase cleavage; variable Aβ effects | Altered beta- or gamma-secretase cleavage; increased Aβ production or aggregation |
| Protein function | Catalytic subunit of gamma-secretase complex | Catalytic subunit of gamma-secretase complex | Transmembrane protein; precursor of amyloid-beta peptide |
The APP gene on chromosome 21q21.3 encodes the amyloid precursor protein, a 770-amino-acid type I transmembrane glycoprotein. Pathogenic APP mutations cluster near the secretase cleavage sites that generate amyloid-beta peptides, and their effects on Aβ metabolism define distinct mechanistic categories O'Brien & Wong, 2011 [4].
| Mutation | Amino Acid Change | Location | Mechanism | Key Clinical Features |
|---|---|---|---|---|
| Swedish | K670N/M671L | Beta-secretase site | Increases beta-secretase | |
| London | V717I | Gamma-secretase site | Shifts gamma-secretase cleavage to favor Abeta42 over Abeta40; increases Abeta42/40 ratio | Onset ~45-55 years; first FAD mutation identified in APP (Goate et al., 1991) |
| Arctic | E693G (E22G in Abeta) | Within Aβ domain | Increases Abeta protofibril formation; promotes rapid oligomerization; paradoxically low amyloid PET signal | Onset ~52-57 years; Arctic mutation carriers may have negative amyloid PET despite heavy amyloid load due to non-fibrillar plaque morphology |
| Iowa | D694N (D23N in Abeta) | Within Abeta domain | Promotes Abeta fibril formation; severe cerebral amyloid angiopathy | Onset ~50-66 years; prominent cerebrovascular amyloid; hemorrhagic strokes |
| Icelandic (A673T) | A673T (A2T in Abeta) | Beta-secretase site | Reduces BACE1 cleavage by approximately 40%; decreases Abeta40 and Abeta42 production by ~28% | Protective: carriers have approximately 5-fold reduced risk of AD and slower age-related cognitive decline |
The Icelandic A673T variant, discovered in 2012 by Jonsson et al., is the only known APP mutation that protects against AD. Located at the same [beta-secretase cleavage site as the pathogenic Swedish mutation but exerting the opposite biochemical effect, A673T reduces Abeta production throughout life Jonsson et al., 2012. This discovery provided compelling human genetic evidence that lifelong reduction in Abeta production is sufficient to prevent AD, strongly supporting therapeutic strategies aimed at reducing amyloid burden [5].
PSEN1 on chromosome 14q24.3 encodes presenilin 1, the catalytic subunit of the gamma-secretase complex that cleaves APP within its transmembrane domain to generate Abeta peptides. With over 300 identified pathogenic mutations, PSEN1 is the most common cause of FAD and is responsible for 50-70% of all autosomal dominant AD cases Cacace et al., 2016 [6].
PSEN1 mutations cause the earliest-onset FAD, with some variants (S169L, intron 4 deletion) producing symptoms as early as 23-25 years. Mean onset is approximately 43 years (range 24-60), and penetrance is virtually complete Ryman et al., 2014 [7].
Mutations cluster in transmembrane domains (TM2, TM6, TM7) and hydrophilic loops critical for gamma-secretase catalytic function. The predominant mechanism involves a shift in gamma-secretase processivity: mutant presenilin 1 produces a higher Abeta42/Abeta40 ratio. This "qualitative shift" hypothesis is validated by studies showing that cell-based Abeta42/40 ratios correlate with clinical age of onset across more than 100 PSEN1 mutations Szaruga et al., 2017 [8].
PSEN2 on chromosome 1q42.13 encodes presenilin 2, which shares approximately 67% amino acid homology with presenilin 1 and also functions as a catalytic subunit of gamma-secretase. Approximately 18 pathogenic PSEN2 variants have been identified, of which 7 are classified as highly pathogenic, making PSEN2 mutations the rarest cause of autosomal dominant FAD Jayadev et al., 2010 [9].
Duplication of the APP locus causes a rare FAD form with onset in the 50s, demonstrating that increased APP gene dosage alone suffices to cause AD Rovelet-Lecrux et al., 2006. This directly explains AD in Down syndrome (trisomy 21), where three copies of chromosome 21 produce ~1.5-fold APP overexpression. Individuals with Down syndrome develop amyloid-beta plaques by their 30s-40s and clinical dementia typically by age 50-55, with two-thirds diagnosed by age 65. [A case study of a man with partial trisomy 21 lacking APP triplication showed no amyloid pathology, confirming APP as the necessary driver Doran et al., 2017 [10].
[DIAN] is an international consortium that has enrolled over 500 FAD family members. It has produced landmark findings on biomarker changes in presymptomatic carriers Bateman et al., 2012:
These findings established the concept of a long presymptomatic phase in AD and motivated prevention trials targeting amyloid pathology before irreversible neurodegeneration occurs [11].
The [DIAN]-TU platform trial (DIAN and improved multiple downstream biomarkers including synaptic degeneration markers, microglial activation markers, and astrocyte reactivity markers Salloway et al., 2025. The [DIAN]-TU Amyloid Removal Trial (ART), initiated in 2024, is now evaluating lecanemab in this population [12].
The Alzheimer's Prevention Initiative (API) AD Colombia trial enrolled 252 cognitively unimpaired carriers of the PSEN1 E280A Paisa mutation from the Colombian kindred. Two-thirds of participants carried the mutation, with treatment beginning a median of 12 years before expected symptom onset. Crenezumab, an anti-amyloid antibody targeting multiple Abeta species, did not meet its co-primary endpoints of slowing decline on the API AD composite cognitive score or the Free and Cued Selective Reminding Test Cueing Index Tariot et al., 2022. The trial did show a nominal trend toward slowing tau] accumulation and cognitive decline in certain subgroups. A subsequent trial using donanemab in this population is now underway [13].
Genetic testing for FAD mutations is recommended for individuals with a family history suggestive of autosomal dominant inheritance and symptom onset before age 65. Testing is available for PSEN1, PSEN2, and APP through clinical genetic laboratories. Key considerations include:
The study of Familial Alzheimer's Disease Genetics has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration/mechanisms) and continues to drive therapeutic development [14].
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions [15].
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 33% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 42%